|
|
|
| |
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms ( ), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.
|
|
|
|
|
|
|
Know the novel hemostatic drug generation TT-103MH got through BioplatformScreen by Thrombotargets. For topical treatment of bleeding disorders.
Novel and significantly radical approach for the treatment of bleeding disorders, using a topical formulation. See all antihemorrhagic information of new discover TT-103MH for bleeding disorders.
Thrombotargets is the biotech company that develops new medicines (recombinant DNA, molecular biology and small molecule drug technologies) for superficial thrombosis and other kinds of coagulation diseases.
|
|
|
|
